Annals of Inquiry

Why Do Mind-Altering Drugs Make People Feel Better?

致幻药物为何能让人感觉良好?
Scientists want to redesign psychedelics so that they don’t induce a trip—but they still improve mental health.
科学家们正试图重新设计致幻剂,使其在不引发迷幻体验的同时,仍能改善心理健康。
silhouette coming together mind expansion
Illustration by Dhrutika Khimani

In the year 2000, a team of Yale researchers published a surprising paper. The team had given ketamine, a mind-altering drug that is normally used to anesthetize patients during surgery, to ten people with depression. All but one reported a marked improvement in their symptoms after one dose. Curiously, the antidepressant effect emerged after the mind-altering experiences and persisted for more than a week, suggesting that ketamine might be doing more than making the patients trip. Around the same time, researchers at Johns Hopkins gave volunteers psilocybin, the active component in hallucinogenic mushrooms, to study its psychological effects. The U.S. has treated psilocybin as an illegal Schedule I substance for more than half a century, but, fourteen months after the experiment, many participants considered it one of the most meaningful experiences of their lives—akin to the birth of a child.

2000年,耶鲁大学的一个研究团队发表了一篇令人惊讶的论文。该团队给十名抑郁症患者服用了氯胺酮(ketamine)——一种通常在手术中用于麻醉病人的致幻药物。除一人外,所有受试者在单次用药后都报告症状明显改善。耐人寻味的是,抗抑郁效果在致幻体验消退后才显现,且持续超过一周,这表明氯胺酮的作用可能不止是让患者产生幻觉。大约同一时期,约翰斯·霍普金斯大学的研究人员为探究裸盖菇素(psilocybin,致幻蘑菇中的活性成分)的心理效应,给志愿者服用了该物质。尽管美国将裸盖菇素列为非法一级管制药物已逾半个世纪,但在实验结束十四个月后,许多参与者仍视其为人生中最有意义的经历之一——堪比子嗣诞生。

A chemical neuroscientist named David Olson, then a graduate student at Stanford, told me that he encountered these studies and was “struck by the ability of a substance, with a single dose, to have such long-lasting effects.” He wanted to know how the drugs worked. He followed closely as researchers began investigating the effects of mind-altering substances on depression, anxiety, substance-use disorders, post-traumatic stress disorder, and other conditions. These studies often identified positive results, sometimes marked ones, and they sparked discussions about a new mental-health paradigm. Might we one day take psychedelics as a kind of therapy? How would clinicians safely prescribe substances that change our perceptions, thoughts, and moods? And perhaps the most perplexing question of all: Why would such drugs make us feel better in the first place?

一位名叫戴维·奥尔森(David Olson)的化学神经科学家告诉我,他读到这些研究时,“被一种物质仅凭单次剂量就能产生如此持久效果的能力所震撼”。当时他还是斯坦福大学的研究生,想知道这些药物如何发挥作用。随着研究人员开始研究致幻物质对抑郁症、焦虑症、物质使用障碍、创伤后应激障碍等病症的影响,他密切关注着相关进展。这些研究常常发现积极效果,有时甚至是显著效果,并引发了关于心理健康新范式的讨论。有朝一日,我们是否会将致幻剂作为一种疗法?临床医生如何安全地开具这些改变我们感知、思维和情绪的药物?而或许最令人困惑的问题是:为什么这类药物首先能让我们感觉更好?

An important clue came in 2010, when another team at Yale published a study of how ketamine affected the brain cells of rats. In the prefrontal cortex, which regulates mood, the drug seemed to prompt brain cells to grow new branch-like projections that help neurons connect with one another. These projections, known as dendritic spines, typically develop as we learn, gain skills, and experience new things, and their growth contributes to what scientists call neuroplasticity—the brain’s ability to change structurally and functionally over time. Stress and depression, meanwhile, can make them wither like dying trees—especially in the prefrontal cortex. (New dendrites aren’t always a good thing; part of cocaine’s addictiveness is thought to come from excessive growth in the brain’s reward centers.) Before administering the ketamine to the rats, the Yale researchers induced symptoms of depression by subjecting the animals to grim protocols such as “learned helplessness” and a “forced swim test.” The drug not only bolstered dendrites but also improved the rats’ behaviors. Yet when the researchers blocked key proteins involved in dendritic growth, the improvements disappeared—a suggestion that the drug’s mental-health effects might depend on the growth.

一个重要的线索出现在2010年,当时耶鲁大学的另一个团队发表了一项关于氯胺酮如何影响大鼠脑细胞的研究。在调节情绪的前额叶皮层中,这种药物似乎能促使脑细胞长出新的树枝状突起,帮助神经元相互连接。这些被称为树突棘的突起,通常在我们学习、掌握技能和体验新事物时发育,它们的生长有助于科学家所称的神经可塑性——即大脑随时间推移在结构和功能上发生改变的能力。与此同时,压力和抑郁则可能使它们像枯树般萎缩——尤其在前额叶皮层。(新生的树突并非总是好事;可卡因之所以容易成瘾,部分原因被认为与大脑奖赏中心的过度生长有关。)在给大鼠施用氯胺酮前,耶鲁的研究人员通过“习得性无助”和“强迫游泳测试”等严酷实验手段,诱导出动物的抑郁症状。这种药物不仅增强了树突,还改善了大鼠的行为。然而,当研究人员阻断参与树突生长的关键蛋白质时,这些改善便消失了——这表明药物的心理健康效应可能依赖于这种生长。

Olson designed similar experiments with several psychoactive drugs: psilocin (the active form of psilocybin), LSD, DMT, MDMA. In a 2018 paper, he and several colleagues reported that all of these substances spurred dendrite growth in isolated neurons in a dish. When they dosed fruit flies with LSD, they observed a similar neural response. The researchers then injected DMT into live rodents. Twenty-four hours later, changes were readily apparent in the prefrontal cortex. In several microscope images included in the paper, the rodent neurons look like newly fertilized trees.

奥尔森(Olson)用几种精神活性药物设计了类似的实验:裸盖菇素(psilocin,赛洛西宾的活性形式)、LSD、DMT、MDMA。在2018年的一篇论文中,他和几位同事报告称,所有这些物质都能促进培养皿中离体神经元的树突生长。当他们给果蝇施用LSD时,也观察到了类似的神经反应。随后,研究人员向活体啮齿动物注射了DMT。24小时后,前额叶皮层的变化已清晰可见。论文中附带的几张显微镜图像显示,啮齿动物的神经元看起来像刚被授粉的树木。

Advocates of psychedelic therapy have long argued that altered mental states help explain whatever therapeutic effects these drugs have. Roland Griffiths, who oversaw the Johns Hopkins study of psilocybin, believed that the drug helped people because it sparked mystical experiences. “Very often, people report these experiences to be the most personally meaningful, personally insightful, of their entire lifetime,” he told me before his death in 2023. (Indeed, when Michael Pollan wrote about Griffiths for this magazine, in 2015, his story was titled “The Trip Treatment.”) Olson had a different hypothesis: What if the most important effect of these drugs is not on the mind but on the brain?

迷幻疗法的倡导者长期以来认为,精神状态的改变有助于解释这些药物的治疗效果。负责约翰·霍普金斯大学裸盖菇素研究的罗兰·格里菲斯认为,这种药物之所以能帮助人们,是因为它能引发神秘体验。“人们常常报告说,这些体验是他们一生中最具个人意义、最具个人洞察力的经历,”他在2023年去世前告诉我。(事实上,当迈克尔·波伦在2015年为本刊撰写关于格里菲斯的文章时,他的故事标题就是《迷幻疗法》。)奥尔森则提出了不同的假设:如果这些药物最重要的作用不是作用于心智,而是作用于大脑呢?

Olson became convinced that scientists could take the psychedelic effects out of psychedelic drugs—without sacrificing many of the mental-health benefits. This is a provocative view. “I don’t really buy the basic argument that you can remove the trip entirely and get the therapeutic response,” Robin Carhart-Harris, a psychedelics researcher at the University of California, San Francisco, told me. Carhart-Harris has used fMRI scans to document changes in brain activity that occur during psychedelic experiences. “Imagine the brain’s activity patterns like a snow globe that has settled,” he has said. “Psychedelics shake the snow globe, disrupting these patterns and allowing for new ones to form.” In his telling, a trip is just what you feel when the globe shakes; skip the trip and your brain remains stuck in its patterns.

奥尔森确信,科学家能够去除迷幻药的致幻效果,同时保留其大部分心理健康益处。这一观点颇具争议。“我实在无法认同那种认为完全去除致幻体验仍能获得疗效的基本论点,”加州大学旧金山分校的迷幻药研究者罗宾·卡哈特-哈里斯告诉我。他通过功能性磁共振成像记录了迷幻体验期间大脑活动的变化。“想象一下,大脑活动模式就像已沉淀的雪花水晶球,”他曾这样形容,“迷幻药会摇晃这个水晶球,打乱原有模式,让新模式得以形成。”在他看来,致幻体验正是水晶球摇晃时的感受;若跳过这种体验,你的大脑将困在固有模式中无法突破。

In 2019, Olson co-founded a company called Delix Therapeutics, which says that its “singular focus is pushing the boundaries of neuroscience to treat conditions of the brain.” His academic research takes place at the University of California, Davis, where I went to visit him in his laboratory. He started to make his case by sketching the structure of serotonin, a neurotransmitter that regulates mood, on a piece of paper. He drew two geometric rings, with groups of atoms branching out. Then he pencilled in some methyl groups—CH3—and moved a single oxygen atom from one carbon to another. “That’s psilocin,” he said.

2019年,奥尔森与人共同创立了一家名为Delix Therapeutics的公司,该公司宣称其“唯一目标就是突破神经科学的边界,以治疗大脑疾病”。他的学术研究在加州大学戴维斯分校进行,我去他的实验室拜访了他。他开始阐述自己的观点,在一张纸上画出了血清素的结构,这是一种调节情绪的神经递质。他画了两个几何环,上面有原子团分支。然后他用铅笔添加了一些甲基(CH3),并将一个氧原子从一个碳原子移到另一个碳原子。“这就是裸盖菇素,”他说。

Olson erased the oxygen. Now the molecule was DMT, which causes an extremely intense but relatively short trip. “Small structural changes make a huge difference,” he explained. Finally, he transposed the nitrogen and carbon rings from one position to another. In terms of the molecule’s over-all shape, it was nearly identical to DMT. “If you held models in your hands, you wouldn’t be able to tell them apart,” Olson said. “But they have very different effects.” In rodent experiments, both molecules promote dendritic growth in the prefrontal cortex. This last molecule, however, wasn’t hallucinogenic.

奥尔森(Olson)移除了氧原子。现在这个分子变成了DMT(二甲基色胺),它能引发极其强烈但相对短暂的迷幻体验。“微小的结构改变会产生巨大差异,”他解释道。最后,他将氮原子和碳环从一个位置转移到另一个位置。就分子的整体形状而言,它几乎与DMT完全相同。“如果你把两种分子模型拿在手里,根本看不出区别,”奥尔森说,“但它们的效果却大相径庭。”在啮齿动物实验中,两种分子都能促进前额叶皮层的树突生长。然而,最后这种分子却不具有致幻性。

When Olson was at Stanford, he learned from a mentor who had honed a new method for developing drugs: function-oriented synthesis. Within a given molecule, specific groups of atoms could be catalogued according to their individual effects on the body. If you determined which group did what, then you could potentially synthesize a compound that isolates what you wanted, leaving out the rest. “It’s a very reductionist approach,” Olson said. He compared a chemist using this method to a mechanic working on a car. “It’s got all these complex parts,” he said. But those parts can be grouped by function—axles go in this bin, spark plugs go in that bin—and you could change the car’s performance by adjusting its components. Olson’s theory was that one part of a psychedelic molecule caused a trip, while another stimulated dendritic growth. If he could remove some of the former but preserve a little of the latter, then he might have a recipe for a non-psychedelic psychedelic medicine.

在斯坦福求学时,奥尔森师从一位导师,这位导师开创了一种研发药物的新方法:功能导向合成法。在特定分子中,原子团可根据其对人体产生的不同效应进行分类。若能确定各原子团的功能,就有可能合成出仅保留所需功效、剔除其他作用的化合物。“这是一种非常还原论的方法,”奥尔森说。他将运用此法的化学家比作修车技师:“汽车由众多复杂部件组成。”但这些部件可按功能分类——车轴归入这类,火花塞归入那类——通过调整零部件就能改变车辆性能。奥尔森的理论认为:致幻分子中某部分引发迷幻体验,另一部分则刺激树突生长。若能削弱前者而保留后者,或许就能研制出无致幻作用的迷幻药物。

Olson, who has a shaved head and piercing eyes, showed me how the scientists in his lab break psychedelic molecules into parts, as though they’re cars in a chop shop, and build new ones. There were beakers everywhere, full of chemical reagents such as sodium hydrosulfite and inorganic bases. We walked by liquid-chromatography machines and hulking specimen freezers. Graduate students in tie-dye shirts worked under fume hoods; on the glass that protected them from chemicals, synthesis reactions were scribbled in black marker. One researcher, Andrian Basargin, explained that he was making a substructure of LSD in an acetone and dry-ice bath. It would become a component in a new compound, which would then be taken for a test drive.

奥尔森(Olson)剃着光头,目光锐利。他向我展示了实验室里的科学家如何将迷幻分子拆解成部件,就像拆车厂里的汽车一样,然后重新组装成新的分子。到处都是烧杯,里面装满了连二亚硫酸钠和无机碱之类的化学试剂。我们走过液相色谱仪和庞大的样本冷冻柜。身穿扎染衬衫的研究生在通风橱下工作;保护他们免受化学品侵害的玻璃上,用黑色记号笔潦草地写着合成反应式。一位名叫安德里安·巴萨金(Andrian Basargin)的研究员解释说,他正在丙酮和干冰浴中制备LSD的亚结构。这将成为新化合物的一个组成部分,然后接受“试驾”。

Olson got hints on where to begin from an odd pair of books by Alexander and Ann Shulgin: “PiHKAL,” short for “Phenethylamines I Have Known and Loved,” and “TiHKAL: The Continuation,” short for “Tryptamines I Have Known and Loved.” Alexander was a chemist who, beginning in the nineteen-sixties, created nearly two hundred novel chemical compounds, many of them psychedelic, and tested some of them on himself. The books contain extensive notes on the drugs’ synthesis and effects. Olson tasked a grad student with reading the books and cross-referencing drug forums on Reddit—“kind of a weird thing,” he admitted. He wanted to know which of Shulgin’s concoctions didn’t produce much of a trip. “Some of the first molecules we made were informed by procedures from those books,” he told me.

奥尔森从亚历山大·舒尔金(Alexander Shulgin)和安·舒尔金(Ann Shulgin)夫妇的两本奇特著作中获得了研究线索:《PiHKAL》(全称《我所知晓与钟爱的苯乙胺》)和《TiHKAL:续篇》(全称《我所知晓与钟爱的色胺》)。亚历山大是位化学家,自二十世纪六十年代起,他创造了近两百种新型化合物,其中许多具有致幻性,部分化合物他还在自己身上进行了测试。这两本书详细记载了这些药物的合成方法与作用效果。奥尔森让一名研究生研读这两本书,并对照Reddit上的药物论坛进行交叉验证——“这确实有点古怪”,他坦言道。他想知道舒尔金调配的哪些化合物不会产生强烈的迷幻体验。“我们最早合成的几种分子,其制备方法正是从那些书中获得的。”他告诉我。

A long trial-and-error process gave Olson a sense of which molecular motifs seemed likely to cause mind-altering effects. “You make a change, you do a round of testing, then you see, Oh, this change takes us closer to where we want to be,” he said. He showed me a large black box about the size of an industrial printer. Inside were lab-grown cells studded with modified receptors. A new substance would be squirted over the cells, Olson explained. If the molecule was likely to have hallucinogenic properties, it would trigger a fluorescence reaction that sensors in the box would detect. This helped the team weed out trippy compounds. In this way, for example, the team discovered that flipping two atoms within the LSD molecule—Olson compared the change to a tire rotation—affected how hallucinogenic it was. To confirm these findings, this new compound was also tested on rodents.

经过漫长的试错过程,奥尔森逐渐掌握了哪些分子结构可能引发致幻效应。“你做出一次调整,进行一轮测试,然后会发现:哦,这个改动让我们离目标更近了。”他向我展示了一个工业打印机大小的黑色箱体,内部培养着嵌有改造受体的细胞。奥尔森解释道,新物质会被喷洒到细胞上,若分子可能具有致幻特性,就会触发荧光反应,由箱内传感器捕捉。这套系统帮助团队筛选出致幻化合物。例如,他们发现将LSD分子中的两个原子位置互换——奥尔森将这种调整比作轮胎换位——会改变其致幻强度。为验证这些发现,团队还在啮齿动物身上测试了这种新化合物。

If a molecule passed these tests, the next step was to determine whether it stimulated the growth of dendrites. In another lab across Davis’s leafy campus, we met John Gray, a neuroscientist who tested experimental drugs on living neurons. Slices of mouse brain floated in dishes of synthetic cerebrospinal fluid; on a monitor, I could see a single teardrop-shaped neuron. I watched through a microscope as a postdoc, Raghava Jagadeesh Salaka, broke through the neuron’s cell membrane with a micropipette. It looked like a needle pricking a dollop of translucent jelly.

如果一种分子通过了这些测试,下一步就是确定它是否能刺激树突生长。在戴维斯校园另一侧绿树成荫的实验室里,我们见到了神经科学家约翰·格雷(John Gray),他在活体神经元上测试实验性药物。小鼠脑切片漂浮在人工脑脊液培养皿中;监视器上,我能看见一个泪滴状的神经元。透过显微镜,我看着博士后拉加瓦·贾加迪什·萨拉卡(Raghava Jagadeesh Salaka)用微吸管刺破神经元细胞膜——那景象如同针尖刺入一团半透明果冻。

The micropipette allowed the researchers to measure electrical activity in the neuron, Gray explained. Blue spikes, which suggested increased signalling and connectivity, soon appeared on another computer monitor. The team also looked for physical changes. After exposing neurons to a compound, they used a microscope to count any new dendritic spines that had popped up.

格雷解释道,微量移液器让研究人员得以测量神经元的电活动。另一台电脑显示器上很快出现了蓝色尖峰信号,这预示着信号传递与连接性正在增强。研究团队同时观察着物理层面的变化——在将神经元暴露于某种化合物后,他们通过显微镜计数那些新冒出来的树突棘。

Olson eventually found a substance that did not seem to be hallucinogenic but potently stimulated growth in the cortical neurons of rodents. He named the compound zalsupindole; it was similar to the variant of DMT that he’d sketched for me in his lab. He felt he needed a term for this new category of drug, so a classics professor at Davis helped him come up with “psychoplastogen,” from the Greek roots psych (“mind”) and plast (“molding”). Delix, the company that he co-founded, tends to use the term “neuroplastogens,” which emphasizes the impact on the brain rather than on the mind. I asked Olson what he thought it might be like for a person to take it. “Well, we started clinical trials two weeks ago,” he told me.

奥尔森最终发现了一种似乎不会致幻、却能有效刺激啮齿动物皮层神经元生长的物质。他将这种化合物命名为扎舒平多(zalsupindole),其化学结构与他曾在实验室向我描绘过的DMT变体相似。他感到需要为这类新药创造专属术语,于是戴维斯分校的一位古典学教授帮他构想了“精神塑形剂(psychoplastogen)”这个词,词源来自希腊语中的“心灵(psych)”与“塑造(plast)”。他联合创立的德利克斯公司(Delix)更倾向于使用“神经塑形剂(neuroplastogens)”这个术语,强调其对大脑而非心智的影响。当我询问他认为人类服用这种药物会产生何种体验时,他告诉我:“我们两周前已启动临床试验。”

In December, Delix Therapeutics presented the results of what it called the first human clinical trial of a neuroplastogen. Eighteen patients with major depression were treated with zalsupindole for one week in a monitored setting. There were no significant safety concerns, and the team confirmed that the drug has no subjective effects. “Definitely, without a doubt, it is not hallucinogenic,” Olson said. Although the study was designed primarily to establish safety, almost all of the participants reported substantial improvements in their symptoms for at least a month. Two participants mentioned that their depression had abated completely. Edward Sellers, an emeritus professor at the University of Toronto and an expert on pharmacology who is not affiliated with Delix, told me that results were “encouraging but inconclusive.” He stressed that the trial was limited by its small size, its lack of a placebo control, and the fact that participants knew what they were taking. But it was enough to convince the Food and Drug Administration to approve a larger, placebo-controlled study in the coming years and to allow participants to take the drug at home.

去年12月,德利克斯治疗公司公布了其所谓的首个人类神经可塑原临床试验结果。18名重度抑郁症患者在一周内接受了扎舒平多治疗,整个过程处于监测环境中。未发现重大安全隐患,研究团队确认该药物没有主观效应。“毫无疑问,它绝对没有致幻性,”奥尔森表示。虽然这项研究主要旨在确定安全性,但几乎所有参与者都报告称,他们的症状在一个月内得到了显著改善。两名参与者提到他们的抑郁症已完全缓解。多伦多大学荣休教授、药理学专家爱德华·塞勒斯(未参与德利克斯公司研究)告诉我,这些结果“令人鼓舞但尚不确定”。他强调该试验存在局限性:样本量小、缺乏安慰剂对照,且参与者知晓自己服用的是何种药物。但这些数据已足以说服美国食品药品监督管理局批准在未来几年开展更大规模的安慰剂对照研究,并允许参与者在家服药。

Many of the scientists I consulted for this story predicted that Olson’s approach would not be effective. “I think it’s really far-fetched,” Griffiths told me, in 2023. His emphasis on mystical experiences—often featuring an “authoritative sense of unity or connectedness,” “positively valenced feelings such as love or peace,” and a sensation of “oceanic boundlessness”—has heavily influenced psychedelic research. In 2022, a review of twelve studies of psychedelic therapies for depression, cancer-related distress, and substance-use disorders found a significant association between mystical experiences and mental-health benefits. (It also warned that studies tend to be small, unrepresentative of the wider population, and susceptible to bias.) Many researchers believe that removing the mind-altering effects from psychedelic drugs would undermine any benefits. “The evidence suggests that, in doing so, you’re just going to engineer out the therapeutic effect,” Gül Dölen, a neuroscientist at the University of California, Berkeley, told me.

为本文接受采访的许多科学家都预测,奥尔森的方法不会有效。“我认为这真的不太现实,”格里菲斯在2023年告诉我。他对神秘体验的强调——通常包括“权威性的统一或连接感”“积极的情感体验如爱或平静”以及“无边无际的海洋感”——已经深刻影响了迷幻药研究。2022年,一项针对迷幻药治疗抑郁症、癌症相关痛苦和物质使用障碍的12项研究的综述发现,神秘体验与心理健康益处之间存在显著关联。(该综述也警告说,这些研究往往样本量小,不能代表更广泛人群,且容易产生偏倚。)许多研究者认为,去除迷幻药改变心智的效果会削弱其益处。“证据表明,这样做只会把治疗效果也一并剔除,”加州大学伯克利分校的神经科学家居尔·多伦告诉我。

Carhart-Harris, at U.C.S.F., is skeptical that mystical experiences can fully explain why psychedelic drugs help people with depression. “If you look up mystical in the dictionary, you see supernatural, and that’s a problem in my view,” he told me. But his brain-imaging studies suggest that, during a psychedelic trip, communication between different regions of the brain becomes far less constrained than during normal consciousness, allowing new ways of thinking to emerge. Zalsupindole might not produce those effects. Other research has found that psychedelic trips elicit psychological insights and emotional breakthroughs, which are strong predictors of a therapeutic response. “It’s not magic,” Carhart-Harris said. “It’s psychology.” David Nichols, a neuroscientist who is an expert on psychedelics, told me about a woman with alcohol-use disorder who realized during a psilocybin trip that her drinking was harming her children and decided to stop. Another patient had a revelation about the origins of his severe obsessive-compulsive disorder, which significantly improved his symptoms. “There is something that happens that is transformative,” Nichols said. “It’s not just the physiological effect of making some dendrites grow.”

加州大学旧金山分校的卡哈特-哈里斯对迷幻体验能否完全解释致幻剂为何能帮助抑郁症患者持怀疑态度。“如果你查字典里'神秘'这个词,会看到'超自然'的解释,在我看来这是个问题,”他告诉我。但他的脑成像研究表明,在迷幻体验期间,大脑不同区域间的交流远比正常意识状态下更少受限,从而催生新的思维方式。扎舒平多可能无法产生这些效果。其他研究发现,迷幻体验能引发心理洞察和情感突破,这些是治疗反应的重要预测指标。“这不是魔法,”卡哈特-哈里斯说,“这是心理学。”致幻剂研究专家、神经科学家戴维·尼科尔斯向我讲述了一位酒精使用障碍患者的故事:她在裸盖菇素体验中意识到酗酒正在伤害自己的孩子,于是决定戒酒。另一位患者则对自身严重强迫症的根源产生了顿悟,这显著改善了他的症状。“确实会发生某种具有转化性的体验,”尼科尔斯说,“这不仅仅是促进树突生长的生理效应。”

Many pharmaceutical companies are betting on neuroplastogens, however. One 2024 analysis, published in the journal Nature Biotechnology, estimated that the field could be worth nearly seven billion dollars by 2030. That same year, AbbVie, one of the largest drug companies in the U.S., signed a deal with Gilgamesh Pharmaceuticals, worth roughly $1.95 billion, to develop “novel neuroplastogens.” Another biotech company, Enveric Biosciences, is preparing for human trials of its own non-hallucinogenic analogue of DMT. In September of 2025, the National Institute on Drug Abuse awarded a grant worth up to $11.4 million to atai Life Sciences to develop similar drugs. Neuroplastogens are “quietly redefining the psychedelic medicine narrative,” according to “Microdose,” an industry newsletter. “The result is a shift that feels less like a cultural movement and more like a return to classic pharmaceutical logic, just with radically new science underneath.”

然而,许多制药公司正将赌注押在神经可塑性药物(neuroplastogens)上。2024年发表于《自然·生物技术》期刊的一项分析预测,到2030年,这一领域的市场规模可能接近70亿美元。同年,美国最大的制药公司之一艾伯维(AbbVie)与吉尔伽美什制药公司(Gilgamesh Pharmaceuticals)签署了一项价值约19.5亿美元的协议,共同开发“新型神经可塑性药物”。另一家生物技术公司恩维里克生物科学(Enveric Biosciences)也正准备对其自主研发的无致幻性二甲基色胺(DMT)类似物开展人体试验。2025年9月,美国国家药物滥用研究所向阿泰生命科学公司(atai Life Sciences)提供了高达1140万美元的资助,用于开发同类药物。行业通讯《微剂量》(Microdose)指出,神经可塑性药物正在“悄然改写迷幻药疗法的叙事逻辑”,“这场转变不再像一场文化运动,而更像是回归经典制药逻辑——只不过其底层科学已焕然一新”。

“If you absolutely need the hallucinogenic effects, then these new compounds are not going to be the revolution in psychiatry that people are hoping they will be,” Olson told me. Hallucinogens could trigger schizophrenia or a bipolar episode. A family history of these conditions can exclude patients from treatment. Psychedelic treatment protocols are also resource-intensive, and can involve multiple lengthy sessions with trained facilitators that may not be covered by insurance. In Oregon, where psilocybin therapy was legalized in 2023, a third of new clinics have already closed owing to high operating expenses and treatment costs. There have also been reports of facilitators taking advantage of patients while they were under the influence of mind-altering drugs. Neuroplastogens would fit much more comfortably in the existing apparatus for drug development, regulation, and distribution, without the cultural baggage. “I’ve faced significant criticism for creating non-hallucinogenic analogues of psychedelics,” Olson said. “But why wouldn’t you want to try this, to help as many people as possible?”

“如果你绝对需要致幻效果,那么这些新化合物就不会成为人们期待的精神病学革命,”奥尔森(Olson)告诉我。致幻剂可能诱发精神分裂症或双相情感障碍发作。有这些疾病家族史的患者可能被排除在治疗之外。迷幻疗法方案也耗费大量资源,可能涉及与训练有素的引导师进行多次长时间会谈,而这些费用可能不在保险覆盖范围内。在俄勒冈州,裸盖菇素疗法于2023年合法化,但已有三分之一的新诊所因高昂的运营成本和治疗费用而关闭。还有报告称,引导师在患者受精神活性药物影响时占其便宜。神经可塑性诱导剂将更顺畅地融入现有的药物开发、监管和分发体系,且没有文化包袱。“我因创造迷幻剂的非致幻类似物而面临严厉批评,”奥尔森说,“但为了帮助尽可能多的人,为什么不尝试这条路呢?”

Even the skeptics are paying close attention. David Yaden, a psychologist at Johns Hopkins whose official title is the Roland Griffiths Professor of Psychedelic Research, described the development of neuroplastogens as a grand experiment. “Scientifically, I’m interested in the question of whether the trip matters,” he told me. Non-psychedelic neuroplastogens may test that question with a new level of specificity. “If it was all just castles in the sky, and the acute subjective effects don’t matter, that would be really interesting,” Yaden went on. “It would undermine my entire perspective.” If that turns out to be the case, he’s open to changing his mind. ♦

就连怀疑论者也在密切关注。约翰斯·霍普金斯大学的心理学家大卫·亚登(David Yaden)——他的正式头衔是罗兰·格里菲斯迷幻药研究讲席教授——将神经可塑性药物的研发称为一场宏大实验。“从科学角度,我感兴趣的问题是:药物致幻体验是否重要,”他告诉我。非致幻类神经可塑性药物或许能以全新的精确度检验这个问题。“如果这一切都只是空中楼阁,药物急性期的主观体验根本无关紧要,那会非常有意思,”亚登接着说,“这将彻底颠覆我的认知框架。”倘若事实果真如此,他愿意改变自己的想法。♦

2 free previews left — register to get 30 translations a month